Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer
Medicus Pharma Ltd appoints Faisal Mehmud, MD as Chief Medical Officer and promotes Edward Brennan, MD, FACS to Chief Scientific Officer & Head of R&D, focusing on expanding drug development pipeline and commercializing novel non-invasive treatments for basal cell carcinoma.
Alzheimer's Disease Therapeutics Companies | Best Treatments
Alzheimer’s disease therapeutics market includes symptomatic treatments (cholinesterase inhibitors, NMDA receptor antagonists) and disease-modifying therapies (anti-amyloid monoclonal antibodies). Market growth driven by aging population, diagnostic advancements, and R&D investments. Market expected to grow from USD 5.5 billion in 2023 to USD 30.8 billion by 2033 at 18.8% CAGR. Major companies include Biogen, Merck, GSK, Novartis, Johnson & Johnson, Bristol Myers Squibb, Sanofi, Pfizer, Teva Pharmaceutical, and AbbVie, each with strategic initiatives and collaborations in Alzheimer’s research.
FDA accepts Dupixent resubmission for review in chronic spontaneous urticaria treatment
FDA accepts Sanofi and Regeneron's resubmitted sBLA for Dupixent in chronic spontaneous urticaria, targeting 18 April 2025 decision. Dupixent, inhibiting IL-4 and IL-13 pathways, showed significant itch and urticaria reduction in LIBERTY-CUPID Phase 3 studies. Safety consistent with established profile; common adverse events include injection site reactions and COVID-19 infections. Dupixent approved for CSU in Japan and UAE, under review in EU, and has broader approvals for various inflammatory conditions.
US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic
FDA reviews Dupixent (dupilumab) sBLA for chronic spontaneous urticaria (CSU) in adults and patients aged 12+ not controlled by H1 antihistamines, with a decision target date of April 18, 2025. LIBERTY-CUPID phase 3 studies support the application, showing Dupixent significantly reduces itch and urticaria activity. Dupixent is approved for CSU in Japan and UAE, under review in EU, and has been approved in over 60 countries for various conditions.
Sarilumab allows steroid taper 'more frequently' vs methotrexate in polymyalgia rheumatica
Sarilumab more effective than methotrexate in enabling steroid taper in polymyalgia rheumatica patients, according to ACR Convergence 2024 data.
Sarclisa recommended for EU approval by CHMP to treat transplant-ineligible newly
Sanofi announces EMA's CHMP positive opinion recommending Sarclisa approval in combination with bortezomib, lenalidomide, and dexamethasone for transplant-ineligible NDMM patients. A final decision is expected soon. Sarclisa's potential as the anti-CD38 therapy of choice is reinforced.
EMA human medicine committee recommends approval of Sanofi's Sarclisa to treat ...
EMA's CHMP recommends Sarclisa + VRd for transplant-ineligible NDMM; Sanofi's Dietmar Berger highlights potential new standard-of-care. FDA approved Sarclisa + VRd for NDMM in 2024. IMROZ phase 3 study supports PFS improvement with Sarclisa + VRd. Sarclisa, a CD38 monoclonal antibody, is approved in over 50 countries for MM treatment.
Isatuximab Plus VRd Earns CHMP Recommendation for Newly Diagnosed, Transplant Ineligible Multiple Myeloma Patients
The CHMP recommended isatuximab (Sarclisa) combined with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplant. Data from the phase 3 IMROZ trial showed isatuximab plus VRd reduced disease progression or death risk by 40.4% compared to VRd alone, with a median progression-free survival not reached in the isatuximab group and 54.34 months in the VRd group.
Where are they now? 4 biotechs that soared then crashed during the pandemic
Many biotechs that rose during the pandemic have faced challenges as their COVID-19 candidates faltered. CureVac, after its mRNA vaccine's low efficacy, restructured and partnered with GSK. Novavax, despite FDA approval, struggled with uptake and faced a clinical hold on its flu/COVID shot. Inovio Pharmaceuticals, once a frontrunner with DNA-based tech, faced controversy and delayed its FDA application. Veru's antiviral sabizabulin was denied EUA and now focuses on GLP-1 related treatments.
© Copyright 2024. All Rights Reserved by MedPath